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Charcot osteoarthropathy or Charcot foot is a disabling complication of diabetes and is associated with poor prognosis and high 
mortality. Its pathogenesis is not fully understood and its treatment is at best symptomatic. Furthermore, it is not known whether 
there is a specific type of neuropathy which affects osteoclastic activity, and thereby leads to reduction of bone mineral density 
and the development of Charcot osteoarthropathy. Recently it has been proposed that there is a difference in the presentation 
of Charcot osteoarthropathy between type 1 and type 2 diabetes. This article reviews the link between underlying osteopenia, 
abnormal biomechanical forces and type of neuropathy, and their varying interaction in the pathogenesis of Charcot osteoar-
thropathy in type 1 and type 2 diabetes. Further attention is drawn to the newly discovered osteoprotegerin/receptor activator 
of nuclear factor kappaB ligand (OPG/RANKL) cytokine system, which controls bone resorption. Increased osteoclastic activity 
in the acute Charcot foot may be associated with altered expression of OPG/RANKL signaling pathway and modulation of the 
OPG/RANKL equilibrium in Charcot osteoarthropathy may provide additional therapeutical option to manage this difficult 
condition. Biomed Rev 2005; 16: 43-48.
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INTRODUCTION
Charcot osteoarthropathy or Charcot foot is a major complica-
tion of diabetes and its pathogenesis remains poorly under-
stood (1). It often presents without warning and can rapidly 
deteriorate into severe and irreversible foot deformity leading 
then to ulceration and amputation. Prognosis of this condi-
tion is poor and mortality is high (2,3). There is considerable 
controversy regarding its pathogenesis and the treatment is at 
best symptomatic. Natural history studies have indicated that 
the important initial lesions are fractures which are spontane-
ous in most cases. Due to underlying peripheral neuropathy, 
the fractures are not painful and the patient who is unaware 
of the condition is able to tolerate walking. Eventually a stage 
with multiple fractures and loss of normal foot architecture 
develops, that is, the Charcot foot (4). 
Fractures are often juxta-articular and can cause the joint to 
become unstable and subject to abnormal stresses which will 
result in erosion of bone and cartilage. Fractures of significant
magnitude were responsible for initiating joint changes in the 
majority of the 118 cases of Charcot foot reported by Johnson 
(4). In this classical review, he was convinced that fractures are 
the harbinger of the Charcot foot (5). However, the reason for 
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these fractures is not fully understood. It is possible that there 
is increased fragility of bone associated with a reduction of 
bone density in the foot that would increase susceptibility to 
fracture. Alternatively, these may be stress fractures, occurring 
in bones with normal bone density but subjected to abnormal 
biomechanical forces. Furthermore, it is not known whether 
there is a specific type of neuropathy which by affecting
osteoclastic activity, leads to reduction of bone mineral density 
and the development of Charcot osteoarthropathy. 
IS THERE UNDERLYING OSTEOPENIA THAT PREDISPOSES 
TO FRACTURES AND THEN TO THE DEVELOPMENT OF THE 
CHARCOT FOOT?
Previous studies have suggested that reduced bone mineral 
density in diabetic patients predisposes to fracture, leading 
to Charcot osteoarthropathy. A reduced bone mineral density 
in the lower limbs of Charcot patients compared with non-
Charcot neuropathic patients has been reported (6) as well 
as reduced stiffness in the calcaneum in the Charcot and 
non-Charcot foot compared with controls (7). However, 
these studies did not differentiate between type 1 and type 
2 diabetes and we demonstrated that at the onset of Charcot 
osteoarthropathy, there is a pre-existing osteopenia only in 
type 1 but not in type 2 diabetes as indicated by a reduced 
bone mineral density in the non-Charcot foot compared with 
controls (8) and a recent study has shown a link between type 
1 diabetes, osteopenia and fractures (9). 
Thus the association between diabetes and osteopenia 
is more marked in type 1 rather than type 2 diabetes and 
interestingly a relatively high preponderance of patients 
with longstanding type 1 diabetes developing Charcot 
osteoarthropathy at a young age has been reported (10). This 
overrepresentation of type 1 diabetes suggests that there may 
be additional predisposing factors to Charcot osteoarthropathy 
in type 1 diabetes and underlying osteopenia may be one of 
them.
IS THERE A BIOMECHANICAL ABNORMALITY THAT MAY 
LEAD TO FRACTURES IN BONES WITH NORMAL BONE 
MINERAL DENSITY AND THUS LEAD TO THE DEVELOPMENT 
OF THE CHARCOT FOOT?
It is possible that fractures in type 2 diabetes are result of 
abnormal biomechanical forces on the background of global 
neurological deficit. Indeed, stress fractures of the bone were
the most frequent cause of Charcot osteoarthropathy in one 
series of patients (5). Fractures may result from alteration 
of weight bearing and load in the foot. Armstrong reported 
elevated peak plantar pressures in the Charcot foot and 
interestingly also in the non-Charcot foot in type 2 diabetic 
patients (11) and patients with Charcot osteoarthropathy who 
presented with dislocation pattern of osteoarthropathy had 
a higher bone mineral density compared with patients who 
presented with fractures (9). Weight-bearing on a neuropathic 
foot with weak ankle dorsiflexors causes the triceps surae to
forcefully plantarflex the foot resulting in increased pressure
over the metatarsal-phalangeal joints, a slapping gait and stress 
at the tarsometatarsal, naviculo-cuneiform and midtarsal joints 
once calf contracture occurs (1). Achilles tendon shortening 
may predispose to Charcot foot collapse (12) by pulling 
the hind foot into plantar flexion which results in markedly
increased load in the forefoot (13). Thus high peak pressure 
and sensory neuropathy in the forefoot coupled with a relative 
equinus deformity may predispose to Charcot osteoarthropathy 
(11) as a consequence of an increased pressure in the mid-foot. 
Recent studies have shown that the equinus foot alters the 
normal profile of footfall, moving initial contact away from
the lateral aspect of the heel to the forefoot area, in essence 
missing the load response phase of gait (the first rocker). This
will result in forces of approximately 1.5-2 times body weight 
being transmitted to a region with limited extrinsic shock 
absorption properties. Furthermore, due to the foot’s normal 
pronation profile, a forefoot impact may result in excessive
stress at the articulations of the medial cuneiform, resulting in 
micro- and eventual macrotrauma (14). This may explain why 
the tarsometatarsal joint (Lisfranc joint) is the commonest site 
of involvement of Charcot osteoarthropathy (1) and increased 
pressure in the forefoot may result in fracture/dislocation of 
the tarsometatarsal joint and eventual collapse of the medial 
longitudinal arch. Thus abnormal foot biomechanics in the 
insensate neuropathic limb may lead to repetitive trauma and 
result in fractures and development of Charcot foot.
Although both osteopenia and abnormal biomechanical 
forces in the background of neuropathy may have varying 
interaction in the pathogenesis of Charcot osteoarthropathy in 
type 1 and type 2 diabetes, the final common precipitating event
is usually trauma, which determines the site of involvement 
on the background of peripheral neuropathy, which has been 
demonstrated in both type 1 and type 2 patients with Charcot 
osteoarthropathy.
IS THERE A SPECIFIC TYPE OF NEUROPATHY THAT MAY 
LINK OSTEOPENIA AND DIABETES?
Several investigations have shown that neuropathy may 
aggravate the deficit of bone mass in type 1 diabetes. A
decreased bone mineral density in the femoral neck and 
distal limb in association with peripheral neuropathy has been 
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reported (15) and using quantitative ultrasound, significantly
reduced bone mineral density in the calcaneum in patients 
with severe neuropathy has been demonstrated (16). However, 
the type of neuropathy leading to osteopenia has not yet been 
investigated. Furthermore, once Charcot osteoarthropathy has 
developed there is a reduction of bone mineral density in the 
Charcot foot compared with the non-Charcot foot in both type 1 
and type 2 diabetes. The reasons for this underlying osteopenia 
predisposing to the development of Charcot osteoarthropathy 
in type 1 diabetes and the subsequent reduction in bone mineral 
density in both type 1 and type 2 diabetes, once Charcot 
osteoarthropathy has developed, are unknown but this may 
be related to a specific type of neuropathy.
Clinical observations have indicated that local innervation 
plays a modulating role in bone growth, repair and remodeling. 
Patients with neurological disorders such as spinal cord injury 
and arthritis exhibit localised osteopenia, bone fragility, 
excessive callus formation and altered fracture healing. 
Identification of the nerve-derived signalling molecules,
using immunochistochemistry has enabled the identification
of these nerve fibres of osseous tissues. Calcitonin gene-
related peptide (CGRP) and substance P (SP) have been 
of much interest because these neuropeptides are found in 
unmyelinated (C type) and small myelinated (A-  type) 
primary sensory neurons, namely nociceptive fibres (17,18). 
The terminal structure of the osseous CGRP-containing nerves 
reaches directly osteoblasts, osteoclasts, and periosteal lining 
cells, and are a source of local CGRP which act as a local 
modulator of bone metabolism. CGRP increases osteoblastic 
cyclic adenosine monophosphate via acting on their specific
CGRP receptors (19,20) and thus stimulating osteogenesis 
(21). Osseous CGRP-containing fibres are also involved in
pathologic events of bone. The density of CGRP fibres is 
increased near the sites of postfracture osteogenesis (healing 
callus) (22) and is decreased at the stumps of non-union (23). 
Damage to the CGRP-releasing terminals may result in loss 
of the trophic and modulatory factors provided by the peptide 
transmitters (19-21,24,25). CGRP positive nerve fibres are
crucial element of bone metabolism during growth and 
development and their impairment at a young age may lead 
to impaired bone formation (26). 
Thus small fibre neuropathy may play two possible roles in
the pathogenesis of Charcot osteoarthropathy. Firstly, CGRP 
deficiency, as a result of small fibre neuropathy presenting
at young age in patients with type 1 diabetes, may lead to 
impaired osteogenesis and impede achievement of peak bone 
mass at adolescence and indeed reduced bone mineral density 
has been reported in post-teen age years in patients with type 
1 diabetes (27). Secondly, the loss of CGRP containing nerve 
fibres and their modulatory effect on bone, may lead to impaired
healing of microfractures resulting from a minor trauma in the 
insensate foot in both type 1 and type 2 diabetes, thus triggering 
the development of Charcot osteoarthropathy.
A distinct syndrome has been described in young insulin 
dependent diabetic subjects in their twenties and thirties, often 
women, who develop small fibre neuropathy in association
with Charcot osteoarthropathy (28,29). This is often associ-
ated with symptomatic autonomic neuropathy. Despite their 
youth these patients demonstrate medial calcification of the
arteries of the feet, yet do not experience numbness of their 
feet, retaining normal light touch and near-normal vibration 
perception. The clinical manifestations are almost solely due to 
small nerve fibre damage. This striking syndrome is not rare, is
highly destructive, and is clearly different from the commoner 
problem of numb, ulcerated feet. We have previously described 
an association of neuropathy with vascular calcification but
the mechanism is not fully understood (30).
Thus in type 1 diabetes, there appears to be a syndrome of 
small fibre neuropathy, vascular calcification and peripheral
osteopenia which then results in pathological fractures and 
Charcot osteoarthropathy whilst in type 2 diabetes periph-
eral neuropathy and autonomic neuropathy associated with 
vascular calcification may be present at the time of diagnosis
of type 2 diabetes and thus subsequently increase the risk of 
Charcot osteoarthropathy. 
WHAT THEN COULD EXPLAIN THE LINK BETWEEN SMALL 
FIBRE NEUROPATHY, CALCIFICATION, OSTEOPENIA AND 
CHARCOT OSTEOARTHROPATHY?
A recently described cytokine system, which controls bone re-
sorption may provide this link. This is the osteoprotegerin(OPG)/
receptor activator of nuclear factor-kappaB ligand (RANKL) 
signaling pathway which may be disturbed in diabetic neu-
ropathy (31). A small pilot study has demonstrated increased 
concentrations of OPG in patients with neuropathy compared 
with non-neuropathic patients and healthy controls (32). 
The RANKL has been identified as an essential cytokine
for the formation and activation of osteoclasts. RANKL 
activates its receptor, which is expressed on osteoclasts, 
thus promoting osteoclastogenesis. RANKL is expressed 
on bone forming osteoblasts and thus bone resorption and 
bone formation are coupled through RANKL. The effects of 
RANKL are physiologically counterbalanced by OPG, which 
acts as a decoy receptor (a soluble receptor that acts as an 
antagonist) for RANKL. The balance between RANKL and 
OPG determines osteoclast functions. Expression of RANKL 
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and OPG is coordinated to regulate bone resorption and density 
and negatively by controlling activation state of RANK on 
osteoclasts. Alterations of the OPG/RANKL ratio are critical 
in the pathogenesis of bone diseases that result from increased 
bone resorption (33). Transgenic mice overexpressing OPG 
develop osteopetrosis and, conversely, OPG knockout mice 
develop severe osteoporosis (34). These mice also develop 
arterial calcification which may also be influenced by the OPG/
RANKL cytokine system (35). It is well known that there is a 
high clinical prevalence and coincidence of arterial calcification
and cardiovascular disease in patients with osteoporosis thus 
supporting the hypothesis that the OPG/RANKL system 
may influence both osteoporosis and calcification. (36-38).
Furthermore, there is a significant correlation of serum OPG
levels with diabetes and with cardiovascular mortality and this 
raises the possibility that OPG may be a cause of or a marker 
for arterial calcification (39).
Recent studies on the OPG/RANKL signaling pathway 
provide a deeper understanding of how diverse physiological 
and pathophysiological signals exert their effect on this cy-
tokine pathway to induce osteoclastogenesis, bone resorption 
and skeletal remodeling, and so control bone mass. Mutations 
in the genes encoding RANK and OPG cause bone diseases 
and therefore inhibition of the RANKL signaling pathway 
may be a viable therapeutic strategy for treatment of diseases 
with excessive resorption (40). In a recent study in Charcot 
osteoarthropathy we demonstrated raised levels of OPG in 
type 1 and type 2 patients with Charcot osteoarthropathy com-
pared with type 1 and type 2 diabetic control patients (41). It 
is possible that the increased OPG levels reflect a protective
mechanism to inhibit osteoclast formation and thus compensate 
for increased osteoclastic activity resulting from an increased 
activity of RANKL in acute Charcot osteoarthropathy. The 
RANK/RANKL signaling pathway has been shown to be 
essential for osteoclast differentiation in inflammatory arthri-
tis. Furthermore, imbalance between RANKL and OPG has 
recently been shown to lead to osteoarticular pathology in 
inflammatory arthritis and in severe osteolysis (42). Expres-
sion of OPG/RANKL is known to be modulated by various 
factors including tumour necrosis factor-alpha, interleukins, 
calcitonin, and CGRP. The latter inhibits osteoclast function 
and stimulates bone formation. CGRP is a neuropeptide that 
acts as a neurotransmitter in small fibres (C-fibres) (43,44).
CGRP is deficient in small fibre neuropathy and this may
result in osteopenia via the OPG/RANKL cytokine pathway. 
Small fibre neuropathy may enhance the ratio of RANKL to
OPG and thus promote osteoclastogenesis and accelerate bone 
resorption. Furthermore in Charcot osteoarthropathy, there is 
early fracture which itself stimulates increased expression of 
RANKL. In the presence of neuropathy, with deficiency of
CGRP, this may lead to overexpression of RANKL and an 
increased OPG/RANKL ratio may result in excessive osteo-
clastic activity leading to Charcot osteoarthropathy. 
Thus altered expression of OPG/RANKL secondary to 
small fibre neuropathy may have two roles: (i) by promoting 
osteopenia in type 1 diabetes to increase susceptibility 
to Charcot osteoarthropathy, and (ii) by stimulating 
osteoclastogenesis in the actual development of Charcot 
osteoarthropathy in both type 1 and type 2 diabetes. 
CONCLUSION
Thus the observed difference in bone mineral density in the 
background of sensory deficit may lead to different pathways
in the development of Charcot osteoarthropathy in type 1 
and type 2 diabetes, as determined by the neurovascular and 
neurotraumatic theories of its pathogenesis (1,45). In type 1 
diabetes, the underlying osteopenia secondary to increased 
blood flow and autonomic neuropathy may lead to pathological
fractures and Charcot neuropathic osteoarthropathy as 
described in the neurovascular theory (46). In contrast, 
in type 2 diabetes, where bone mineral density is normal, 
repetitive trauma in the insensitive foot with elevated plantar 
pressure (11,47) as a result of the increased body mass 
index and abnormal biomechanical forces may lead to stress 
fractures and Charcot osteoarthropathy in accordance with the 
neurotraumatic theory. Increased osteoclastic activity in the 
acute Charcot foot may be associated with altered expression 
of OPG/RANKL signaling pathway and modulation of the 
OPG/RANKL equilibrium in Charcot osteoarthropathy may 
provide additional therapeutical target to manage this difficult
condition. 
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